FDA gives emergency approval to rapid, cheap coronavirus antigen test
Abbott Lab's rapid antigen test can be run without lab equipment in 15 minutes.
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
The U.S. Food and Drug Administration has authorized a new, rapid antigen test for COVID-19, which costs $5 and can diagnose an infection in 15 minutes.
The test, made by Abbott Labs, is the size of a credit card and does not require any lab equipment to run. Rather, the device has a similar design to some pregnancy tests, allowing health care providers to read test results directly from the testing card, the FDA said.
A patient is given a nasal swab, which is then inserted into the test card. The test is designed to look for small proteins on the surface of the coronavirus, according to an approval letter from the FDA. If such proteins are present in the sample, the test, known as the "BinaxNOW COVID-19 Ag Card," will display a colored line to indicate a COVID-19 infection.
The test has demonstrated 97.1% sensitivity and 98.5% specificity, according to Abbott. When a test is sensitive, it means that it correctly diagnoses most people who are infected with the virus; whereas when a test is specific, it means it doesn't have many "false positives," according to a previous Live Science report.
Related: Coronavirus live updates
The rapid test also comes linked to an app called NAVICA, which will allow users that test negative to display their results to organizations as a "digital health pass," according to a statement released by Abbott.
"With lab-based tests, you get excellent sensitivity but might have to wait days or longer to get the results," Joseph Petrosino, a chairman and professor of molecular virology and microbiology at Baylor College of Medicine in Houston, Texas said in the Abbott statement. Petrosino’s labs have been leading efforts to provide testing for Baylor College and Harris County in Texas, according to the statement. "With a rapid antigen test, you get a result right away, getting infectious people off the streets and into quarantine so they don't spread the virus,” Petrosino said. But the test is only allowed to be given by healthcare professionals.
Get the world’s most fascinating discoveries delivered straight to your inbox.
The new test is the fourth antigen test to receive "emergency use authorization" (EUA) from the FDA , according to CNN. Emergency use authorization is permission given to unapproved products to be used in an emergency to diagnose, treat or prevent serious or life-threatening conditions, "when there are no adequate, approved, and available alternatives," according to the FDA.
By the beginning of October, Abbott will ship out about 50 million tests a month, according to the statement.
Originally published on Live Science.

Yasemin is a staff writer at Live Science, covering health, neuroscience and biology. Her work has appeared in Scientific American, Science and the San Jose Mercury News. She has a bachelor's degree in biomedical engineering from the University of Connecticut and a graduate certificate in science communication from the University of California, Santa Cruz.
